Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

404 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-06-30

Study Completion Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Contrast-induced nephropathy (CIN) is a well-recognized complication of radiographic contrast administration and is associated with increased short- and long-term mortality. Previous strategies including forced diuresis with diuretics or mannitol, intravenous administration of fenoldopam or dobutamine, and postprocedure hemodialysis to prevent CIN have been largely unsuccessful. In addition, the use of N-acetylcysteine to prevent CIN has yielded conflicting outcomes.

A review of a large insurance database and retrospective study have shown that statins therapy is associated with a lower incidence of CIN after percutaneous coronary intervention. The preventive effect of statins on CIN may be attributed to direct pleiotropic effects on the vascular wall such as improvement of endothelial dysfunction, anti-inflammatory or anti-oxidative effect. However, recent randomized trial could not demonstrate the preventive effect of statin on CIN in patients with chronic kidney disease.

Thus, we will investigate the preventive effect of pitavastatin on CIN in patient with renal dysfunction undergoing coronary angiography or intervention.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Polymorphism of Oxidative Stress Genes in the Pathogenesis and Antioxidant Prevention of Contrast Induced Nephropathy

NCT01142024

Nephropathy Oxidative Stress

COMPLETED NA

Evaluating the Protective Effect of Pentoxifylline on Contrast Induced Nephropathy

NCT01469624

Nephropathy

UNKNOWN NA

Can Remote Ischaemic Preconditioning Reduce Contrast Induced Nephropathy in Patients Receiving Contrast for Computed Tomography?

NCT01741896

Contrast Induced Nephropathy Remote Ischaemic Preconditioning

COMPLETED NA

PROMISS: Simvastatin Prevents the Contrast Induced Acute Renal Failure in Patients With Renal Insufficiency Undergoing Coronary Angiography

NCT00259441

Kidney Failure

COMPLETED PHASE4

Contrast Induced Nephropathy Among Vascular Patients Undergoing Lower Limb Angioplasty

NCT04879186

Contrast-induced Nephropathy

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Contrast-induced Nephropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pitavastatin

Pitavastatin 4 mg/day for 7 days before coronary angiography/intervention

Group Type EXPERIMENTAL

Pitavastatin

Intervention Type DRUG

Placebo

Placebo tablet for 7 days before coronary angiography/intervention

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Sugar pill manufactured to mimic Pitavastatin 4 mg tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pitavastatin

Intervention Type DRUG

Placebo

Sugar pill manufactured to mimic Pitavastatin 4 mg tablet

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Livalo®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 19 years
* Need for coronary angiography or intervention in patients with typical symptoms for angina or myocardial infarction, or documented myocardial ischemia at non-invasive studies including ECG, treadmill ECG test, heart spect or coronary CT angiography
* Estimated glomerular filtration rate ≤60 mL/min
* Informed consent

Exclusion Criteria

* Need for primary percutaneous coronary intervention or emergent intervention in patients with myocardial infarction
* Allergic reaction for contrast agent (Visipaque) or statin
* Contraindication for contrast agent (Visipaque) or statin
* Shock status fron any cause including cardiogenic shock
* Statin use before enrollment (Enrollment after 2 weeks of wash-out period)
* Exposure of contrast agent within 7 days before enrollment
* Pregnancy or Expectation for pregnancy in women of childbearing age
* Heart failure (NYHA class ≥3 or left ventricular ejection fraction \< 40%)
* Acute renal injury
* Dialysis therapy
* Mechanical ventilator
* Life expectancy \< 6 months
* Non-steroidal anti-inflammatory drug, dopamine, mannitol or N-acetylcysteine, ascorbic acid within 48 hours before and after coronary angiography/intervention
* Severe hepatic dysfunction
* Eisenmenger syndrome or idiopathic pulmonary hypertension
* Renal artery angioplasty within 6 months
* Single functioning kidney
* Kidney transplantation

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No